Literature DB >> 19929973

European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI).

M P Bauer1, E J Kuijper, J T van Dissel.   

Abstract

Clostridium difficile infection (CDI) is a potentially fatal illness with an increasing incidence worldwide. Despite extensive ongoing research into CDI treatment, management of CDI still poses important problems, such as a high propensity to relapse and refractoriness to treatment, especially when there is an ileus and oral drugs cannot be administered. This guideline evaluates the available literature, discusses criteria for disease severity and provides recommendations for CDI treatment, indicating level of evidence and strength of recommendation.

Entities:  

Mesh:

Year:  2009        PMID: 19929973     DOI: 10.1111/j.1469-0691.2009.03099.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  98 in total

Review 1.  Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Authors:  Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

2.  Fidaxomicin: in Clostridium difficile infection.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

3.  Hospital-acquired Clostridium difficile infection: determinants for severe disease.

Authors:  J M Wenisch; D Schmid; H-W Kuo; E Simons; F Allerberger; V Michl; P Tesik; G Tucek; C Wenisch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-31       Impact factor: 3.267

4.  Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection.

Authors:  Judith M Wenisch; Daniela Schmid; Hung-Wei Kuo; Franz Allerberger; Verena Michl; Philip Tesik; Gerhard Tucek; Hermann Laferl; Christoph Wenisch
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

5.  Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571.

Authors:  J A Leeds; M Sachdeva; S Mullin; J Dzink-Fox; M J Lamarche
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

6.  Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection.

Authors:  Marco Falcone; Alessandro Russo; Federica Iraci; Paolo Carfagna; Paola Goldoni; Vincenzo Vullo; Mario Venditti
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

Review 7.  Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.

Authors:  Zhong Peng; Dazhi Jin; Hyeun Bum Kim; Charles W Stratton; Bin Wu; Yi-Wei Tang; Xingmin Sun
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

8.  Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.

Authors:  Stuart Johnson; Dale N Gerding; Thomas J Louie; Nancy M Ruiz; Sherwood L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

9.  [Severe infections : causes and management of sepsis].

Authors:  B Salzberger; F Hanses; G Birkenfeld; J Langgartner
Journal:  Internist (Berl)       Date:  2013-08       Impact factor: 0.743

Review 10.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.